A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Sorafenib Plus Erlotinib in Patie

Nothing to do with SIRT, and unfortunate for those on the trial as there was no benefit. However it does avoid a sudden higher hurdle that srx has to jump.

Interesting to see the AE rate on the chemo, really is nasty treatment for many.

Clearly I hope SIRT gets to first line, as a SH, but it may be a huge relief for those with this terrible affliction of it helps avoid some of these AEs.